Eascra Biotech has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $274,990 to conduct research and development (R&D) to advance drug delivery systems capable of effectively targeting solid tumors.
Eascra’s JBNps (Janus base nanoparticles) are an entirely new type of delivery platform that mimics DNA. The platform delivers RNA therapeutics to hard-to-reach treatment sites like joint cartilage, kidneys and solid tumors. Low Earth Orbit (LEO) and microgravity are the perfect environment for JBNps to grow. This creates high-quality, consistent, and stable structures that safely deliver RNA therapies, gene editing technology, and other therapeutics.
NSF accelerates the translation of emerging technologies into transformative new products and services,” said Erwin Gianchandani, NSF Assistant Director for Technology, Innovation and Partnerships. “We take great pride in funding deep-technology startups and small businesses that will shape science and engineering results into meaningful solutions for today and tomorrow.”
This funding enables us to advance the science even further, moving beyond research into the market to help those suffering with arthritis, kidney disease, solid tumor cancers, and other debilitating diseases,” said Mari Anne Snow, Eascra CEO.